US Stock MarketDetailed Quotes
IPA ImmunoPrecise Antibodies
- 1.370
- +0.050+3.79%
Close Apr 29 16:00 ET
- 1.320
- -0.050-3.65%
Post 18:11 ET
36.05MMarket Cap-3285P/E (TTM)
1.390High1.320Low51.69KVolume1.370Open1.320Pre Close70.22KTurnover0.23%Turnover RatioLossP/E (Static)26.32MShares4.22052wk High0.99P/B31.23MFloat Cap0.94052wk Low--Dividend TTM22.79MShs Float33.340Historical High--Div YieldTTM5.30%Amplitude0.940Historical Low1.358Avg Price1Lot Size
ImmunoPrecise Antibodies Key Stats
Quarterly+Annual
YOY
| (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | (Q2)Oct 31, 2022 | (Q1)Jul 31, 2022 | (FY)Apr 30, 2022 | (Q4)Apr 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 81.21%-666K | 93.72%-235K | 93.19%-702K | -99.91%-19.83M | -25.01%-2.23M | 31.26%-3.55M | -85.88%-3.74M | -968.81%-10.31M | -1,553.50%-9.92M | -144.46%-1.79M |
| Net income from continuing operations | 37.47%-2.94M | 64.24%-2.63M | 62.00%-3.57M | -58.96%-26.56M | -10.44%-5.13M | -22.84%-4.7M | -46.74%-7.35M | -190.43%-9.38M | -127.64%-16.71M | 7.73%-4.64M |
| Operating gains losses | -28.36%48K | 71.93%-64K | 727.78%113K | 66.37%-189K | -103.64%-10K | 111.78%67K | -241.61%-228K | 95.80%-18K | -158.91%-562K | -77.71%275K |
| Depreciation and amortization | -22.45%1.31M | -7.58%1.35M | -3.61%1.49M | 77.37%6.69M | 114.15%1.98M | 77.87%1.69M | 56.24%1.46M | 61.96%1.55M | 1.51%3.77M | 3.93%926K |
| Deferred tax | 35.66%-166K | -27.39%-200K | 17.24%-216K | -175.60%-926K | 72.89%-250K | -130.60%-258K | 3.09%-157K | -174.74%-261K | -304.82%-336K | -536.97%-922K |
| Other non cash items | --5K | --5K | 66.67%5K | -64.71%30K | 35.00%27K | --0 | --0 | -87.50%3K | -80.05%85K | -85.61%20K |
| Change In working capital | 268.04%899K | -53.95%1M | 121.71%644K | -662.89%-3.28M | -210.10%-1.95M | 83.46%-535K | 60.95%2.18M | -528.61%-2.97M | 157.17%582K | 250.89%1.77M |
| -Change in receivables | -54.07%497K | 109.69%34K | -33.68%-508K | -312.60%-540K | -1,663.16%-891K | 304.15%1.08M | -169.92%-351K | -268.89%-380K | 652.17%254K | -90.94%57K |
| -Change in inventory | -381.32%-438K | -766.67%-20K | -311.54%-55K | 63.07%-185K | 38.81%-123K | 53.81%-91K | 130.00%3K | 127.96%26K | -58.54%-501K | -2,771.43%-201K |
| -Change in prepaid assets | 104.00%34K | -103.82%-25K | 245.83%175K | 111.66%90K | 361.36%406K | 22.73%-850K | 370.25%654K | -124.90%-120K | 42.47%-772K | -87.57%88K |
| -Change in payables and accrued expense | 233.16%783K | -81.07%437K | 109.94%242K | -213.89%-1.67M | -180.58%-950K | -72.94%-588K | 236.44%2.31M | -3,765.08%-2.44M | 66.89%1.46M | 424.00%1.18M |
| -Change in other working capital | 126.14%23K | 231.51%576K | 1,485.96%790K | -802.16%-976K | -160.55%-393K | 91.75%-88K | -205.29%-438K | -140.43%-57K | 173.16%139K | 161.81%649K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 81.21%-666K | 93.72%-235K | 93.19%-702K | -99.91%-19.83M | -25.01%-2.23M | 31.26%-3.55M | -85.88%-3.74M | -968.81%-10.31M | -1,553.50%-9.92M | -144.46%-1.79M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 125.22%57K | 74.17%-312K | -121.35%-197K | 62.23%-1.97M | 89.15%-444K | 65.96%-226K | -988.29%-1.21M | 73.82%-89K | -112.05%-5.21M | -400.98%-4.09M |
| Net PPE purchase and sale | 167.35%165K | 57.22%-299K | -52.81%-136K | -40.24%-1.5M | -225.35%-462K | 48.20%-245K | -529.73%-699K | 73.82%-89K | 25.30%-1.07M | 75.39%-142K |
| Net intangibles purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---191K | --0 |
| Net business purchase and sale | --0 | --0 | ---146K | 83.97%-592K | 100.49%18K | --0 | ---610K | --0 | -258.79%-3.69M | -623.92%-3.69M |
| Net investment purchase and sale | --0 | -40.98%36K | --85K | --80K | --0 | --19K | --61K | --0 | --0 | --0 |
| Net other investing changes | ---108K | ---- | ---- | 115.44%40K | --0 | --0 | ---- | ---- | ---259K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 125.22%57K | 74.17%-312K | -121.35%-197K | 62.23%-1.97M | 89.15%-444K | 65.96%-226K | -988.29%-1.21M | 73.82%-89K | -112.05%-5.21M | -400.98%-4.09M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 317.38%613K | -259.79%-310K | -166.45%-405K | -121.54%-621K | -112.44%-381K | -452.94%-282K | 136.59%194K | 27.62%-152K | -93.35%2.88M | -89.35%3.06M |
| Net issuance payments of debt | 15.04%-322K | -1.64%-310K | -49.45%-405K | -38.98%-1.34M | -46.92%-382K | -59.92%-379K | -33.19%-305K | -14.83%-271K | -24.61%-962K | -4.42%-260K |
| Net common stock issuance | 863.92%935K | --0 | --0 | -81.40%716K | -99.97%1K | -47.85%97K | 60.45%499K | 357.69%119K | -91.28%3.85M | -88.53%3.33M |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---5K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 317.38%613K | -259.79%-310K | -166.45%-405K | -121.54%-621K | -112.44%-381K | -452.94%-282K | 136.59%194K | 27.62%-152K | -93.35%2.88M | -89.35%3.06M |
| Net cash flow | ||||||||||
| Beginning cash position | -59.70%6.1M | -64.74%6.81M | -72.16%8.37M | -28.18%30.05M | -65.50%11.41M | -60.60%15.15M | -52.61%19.32M | -28.18%30.05M | 1,454.74%41.84M | 109.27%33.07M |
| Current changes in cash | 100.10%4K | 81.97%-857K | 87.65%-1.3M | -83.09%-22.42M | -8.55%-3.06M | 30.98%-4.05M | -132.93%-4.75M | -596.70%-10.56M | -130.37%-12.25M | -110.36%-2.82M |
| Effect of exchange rate changes | -42.90%181K | -74.26%148K | -48.21%-249K | 62.64%740K | 107.92%16K | -36.60%317K | 291.67%575K | -136.76%-168K | 138.69%455K | 82.62%-202K |
| End cash Position | -44.88%6.29M | -59.70%6.1M | -64.74%6.81M | -72.16%8.37M | -72.16%8.37M | -65.50%11.41M | -60.60%15.15M | -52.61%19.32M | -28.18%30.05M | -28.18%30.05M |
| Free cash flow | 86.78%-501K | 87.97%-534K | 91.94%-838K | -90.80%-21.33M | -39.76%-2.7M | 34.89%-3.79M | -109.09%-4.44M | -697.16%-10.4M | -451.46%-11.18M | -85.84%-1.93M |
| Currency Unit | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
